Back to Search
PETER BERGSAGEL, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1316920150IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
33096(AZ)
Education
OTHER
Class of 1984
Research & Publications (20)
Individualizing therapy using molecular markers in multiple myeloma.
PMID 17562256·Clin Lymphoma Myeloma·2007
6-review
Molecular pathogenesis and a consequent classification of multiple myeloma.
PMID 16155016·J Clin Oncol·2005
4-observational
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
PMID 15755896·Blood·2005
8-other
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia.
PMID 19351844·Cancer Res·2009
8-other
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
PMID 19225538·Leukemia·2009
3-trial
High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas.
PMID 19362969·Clin Lymphoma Myeloma·2009
8-other
Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications.
PMID 18974375·Blood·2009
8-other
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.
PMID 19324902·Blood·2009
8-other
Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.
PMID 18216870·Leukemia·2008
8-other
WSU-WM and BCWM.1 should not be assumed to represent Waldenström macroglobulinemia cell lines.
PMID 18650470·Blood·2008
8-other
A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy.
PMID 18414492·Leukemia·2008
6-review
Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity.
PMID 18431519·J Clin Invest·2008
7-preclinical
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.
PMID 18156491·Blood·2008
7-preclinical
Translocation t(4;14) retains prognostic significance even in the setting of high-risk molecular signature.
PMID 17805328·Leukemia·2008
8-other
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.
PMID 18242516·Cancer Cell·2008
7-preclinical
Characterization of MYC translocations in multiple myeloma cell lines.
PMID 18647998·J Natl Cancer Inst Monogr·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 13400 E SHEA BLVD
SCOTTSDALE, AZ 85259 - Phone
- (480) 301-8000
Quick Facts
- NPI
- 1316920150
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 42
- Publications
- 20
Are you this provider?
Claim Your Profile